



Research Tips

University of Colorado Denver

Vice Chancellor for Research: RJ Traystman

11/01/2009

Volume 1 Issue 5

Stimulus Funding Update (ARRA)

As of October 27, 2009, UCDenver submitted 565 grant proposals to NIH, which includes 24 non-ARRA proposals that have received ARRA funding for a total of 110 ARRA awards funded at \$52,139,300.

All 3 CO6 Capital Construction Proposals are pending Council Review.

We have submitted 147 Challenge Grant proposals and have, so far, received 12 of these awards (8.2%) for approximately \$12M. We have submitted 19 GO grant proposals and have, so far, received 2 of these awards (10.5%) for approximately \$4.3M.

COMIRB InfoEd Training

COMIRB will begin training sessions on our new electronic system. The new system will enable you to access information on the status of your protocols in a manner similar to the old protocol manager.

Training will also provide information on electronic submission of protocols. COMIRB hopes to begin the process of accepting documents electronically in November and will start with the Request for Exemption form.

Training sessions will begin October 6 and will be held twice a week until the end of the year in Ed2 North (AMC) room 2201AB. This room holds 30 on a first come first served basis.

Dec.1	2pm - 4pm	Dec. 15	2pm - 4pm
Dec. 3	10am - Noon	Dec. 17	10am - Noon
Dec. 8	1pm - 3pm	Dec. 22	1pm - 3pm
Dec. 10	9am - 11am	Dec. 29	1pm - 3pm

Dr. T's Corner

Two of the grant proposals that we have submitted (Sept. 17, 2009) to NIH as part of the stimulus funding (ARRA) effort focus on renovation improvements to our vivarium. One is for build out of the west wing in the R2 vivarium, to include imaging, behavioral and ABSL3 suites (\$9.9M). The other is for renovation and replacement of cage wash equipment in the R1 vivarium, as well as expansion of the zebrafish suite (\$9.6M).

I would like to thank all of those individuals who participated in the writing and gathering of information on these two renovation proposals, especially Mark Douse. Mark did much of the writing, putting things together, and was able to read and incorporate my many comments into the proposal. In the end, he and Candy Berryman worked hard to get everything submitted properly on line. Mike Barden and John Allison (Facilities); Jeff Olson and Al Roberts (Fentress); Char Warder and Jori Leszczynski (OLAR); thanks for your very hard work in getting the line drawings and price quotations accomplished so quickly. I thought it was pretty amazing, especially since even two weeks prior to submission we were not exactly sure how we were going to bundle these grants. And to everyone else in OLAR, thank you for your proof reading efforts and early discussions. These discussions really helped shape these grant proposals. Finally, thanks to the investigators involved in imaging, behavior, ABSL3 and zebrafish for providing me with the scientific background and justification for build out in each of these areas.



ORDE

Understanding our faculty members' research interests is very important to the Office of Research Development and Education (ORDE). Armed with this information, we can make certain you are aware of upcoming funding opportunities in your areas of interest. We are available to answer your questions on fund searching and proposal development by telephone, e-mail and in-person. We serve both the Anschutz Medical and Downtown Denver Campuses. Our role in the University Research Community is to work directly with faculty and support staff as they strive to achieve excellence in research. ORDE contact: 303-315-5826; research.services@ucdenver.edu

Biosafety

NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines; <http://oba.od.nih.gov/oba/index.html>), administered by the NIH Office of Biotechnology Activities (OBA; http://oba.od.nih.gov/oba/rac/guidelines_02/NIH_Guidelines_Apr_02.htm), apply to all research projects that involve recombinant DNA which are conducted at, or sponsored by an organization, which receives NIH support for recombinant DNA research. Any significant deficiency in compliance with NIH Guidelines or any laboratory accident or exposure to recombinant DNA materials requires a written report to the UCDenver Institutional Biosafety Committee (IBC) (<http://www.uchsc.edu/safety/BioSafety/InstBioSafCommittee.htm>) via the Biosafety Office (biosafety.program@ucdenver.edu), and may require reporting to NIH Office of Biotechnology Activities (<http://oba.od.nih.gov/oba/index.html>) depending upon the nature of the incident. Please be sure to contact the Biosafety Office (303-724-0235) in the event of any incidents or accidents to provide appropriate information for IBC review.

RESEARCH CORNER

Dr. Xiao-Jing Wang, M.D., Ph.D., is the John S. Gates endowed chair and Director of the Head & Neck Cancer Research Program at UCDenver. She is Professor in the Department of Pathology, and has joint appointments in Otolaryngology, Dermatology, and Craniofacial Biology. Dr. Wang's laboratory developed the first genetically engineered mouse model that develops head & neck squamous cell carcinomas (HNSCC) with full penetrance. These lesions mimic human HNSCC at genetic and pathology levels. HNSCC represents the 6th most common cancer type worldwide and its prognosis has not been improved in the past 20 years. Xiao-Jing has brought the best expertise to this campus to continuously develop various HNSCC mouse models, which will add an invaluable resource to our campus for evaluating the mechanisms and efficacy of the existing clinical trials for HNSCC prevention and treatments. Research in Xiao-Jing's laboratory uses both mouse models and human cancer samples for cross-species comparisons. Current activities in her laboratory include: 1) Identification of biomarkers for diagnosis and therapy for human head and neck cancer; 2) Molecular mechanisms of head & neck cancer including the properties of cancer stem cells, transcriptional machinery, and microRNA functions; 3) Experimental therapeutics of head and neck cancer with different genetic alterations; and 4) Tumor microenvironment including the role of inflammation, fibroblast activation and angiogenesis in cancer. In addition to cancer biology, Dr. Wang's laboratory studies molecular mechanisms of inflammatory skin diseases and normal stem cell fate determination during embryonic skin development. Xiao-Jing received her MD and PhD in 1984 and 1989, respectively, from Beijing Medical University in Beijing, China. After completing a Post-doctoral Fellowship at M.D. Anderson Cancer Center in Houston, she became a faculty member at Baylor College of Medicine. In 2003, Xiao-Jing moved to Oregon Health and Sciences University, and in 2008 came to UCDenver. She is a recent recipient of a Challenge Award from NIH.



X-J Wang, MD, PhD

OLAR - New Rule

Over the past several months we have moved the clean mouse colonies in to Suite 4 to better isolate them. Therefore, in an effort to better protect our remaining clean colonies in RC-1, we are reversing our PPE requirements. Effective Monday October 19th, you must wear double PPE in order to enter Suite 4. All other general rodent housing areas will now only require single layer PPE, unless otherwise posted on the room door. Double gowning will still be required in the ABSL suite. To help assist with the transition, there will be signs posted with garbing instructions. In addition, our staff will be available to assist you. If you have any questions or concerns about this or any other procedure in the RC-1 facility, please do not hesitate to contact Jori Leszczynski (303-724-3987; Jori.Leszczynski@UCDenver.edu) or Lorraine Bell (303-724-2317; Lorraine.Bell@UCDenver.edu) who is acting as the RC1 facility manager while Michelle Wallace is out on Maternity Leave.

OLAR Reminders

1. Please do not wear perfumes and strong scents (including cigarette smoke). These can cause problems in animals, especially breeding.
2. Please make sure that cage card requests form and web animal order forms are complete. It is very important to include contact information, including emergency contact information.
3. Please do not write on supplies. These supplies are eventually returned to cage wash where they are redistributed elsewhere and the writing may result in the equipment being unusable, which will ultimately result in higher per diems as the equipment will need to be replaced. If you need to mark equipment (i.e. water left in a water bottle) please use a piece of lab tape.
4. It is preferable that you do not have rodent pets, or reptiles that feed on rodents, at home. If you do have these animals, you should shower and not handle your animal(s) prior to coming to work, as they can be a source of pathogens.
5. In preparation for the decon of RC1, please minimize the amount of disposable supplies that are brought into RC1, as these will need to be discarded during the decon of RC1.

Auraria Libraray

The Auraria Library has a one-year subscription to the Publishing Opportunities database. This database provides regularly updated listings of publishing and presentation opportunities for professors, post-doctoral students and other students. Information from three distinct sources is combined and presented: the Journal Call for Papers includes open opportunities in regularly published journals; and there is also a Conference Call for Papers and a Special Issue Call for Papers. Our subscription expires in July 2010 (unless support funding for continued access is found at that time). All UCDenver campus members may come into the Auraria Library to use this database. Additionally, faculty and students on the UC Denver campus have remote access to Publishing Opportunities. The URL: <http://0-search.ebscohost.com.skyline.cudenver.edu/login.aspx?authtype=ip,uid&profile=ehost&defaultdb=pub>

OLAR

Next Transgenic Core and OLAR Joint Town Hall Meeting Scheduled

The Transgenic Core and OLAR will host the next Town Hall Meeting regarding the Rederivation/Facility Migration process on Monday November 16th at 10:30 AM in Hensel Phelps West.

InfoEd

The second phase of the InfoEd Grant Module will be implemented during fall 2009. This phase, called Proposal Development or PD, will involve electronic routing and electronic proposal development within InfoEd. We look forward to working with Principal Investigators and Research Administrators to implement PD. OGC will be contacting Schools, Colleges, Centers and Departments to begin training soon.